Shares of Affimed AFMD decreased 3.0% in pre-market trading after the company reported Q1 results.
Earnings per share fell 500.00% year over year to ($0.12), which beat the estimate of ($0.14).
Revenue of $5,664,000 decreased by 55.45% from the same period last year, which missed the estimate of $5,930,000.
Affimed hasn't issued any earnings guidance for the time being.
Affimed hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Jun 23, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/n5vo3v39
Recent Stock Performance
52-week high: $3.96
Company's 52-week low was at $1.42
Price action over last quarter: Up 94.55%
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.